跳到正文
原文
Medical Xpress·· 3 天前AI 评分48

脑扫描显示阿尔茨海默病中这两个脑区比海马体更早萎缩

Brain scans reveal two regions that shrink before the hippocampus in Alzheimer's

AI 导读

约翰霍普金斯大学研究团队在《NeuroImage: Reports》发表论文,分析两组独立队列的数百份MRI和PET扫描,发现距状回皮层和杏仁核在疾病早期阶段比负责记忆的海马体出现更大程度的萎缩。研究作者指出这些变化可能在临床症状出现前10年就已显现,有望作为早期阿尔茨海默病预测的生物标志物,但目前仍需更多分子层面研究以转化为临床诊断工具。

正文
Researchers pinpoint earlier evidence of Alzheimer's
This work demonstrates that the entorhinal cortex, in blue, and the amygdala, in red, predict early Alzheimer's disease better than the hippocampus, shown in green. Credit: Johns Hopkins University

Johns Hopkins University researchers have identified two areas of the brain that show significant signs of Alzheimer's disease before it reaches the hippocampus, possibly providing new biomarkers that could get people diagnosed and started on treatment before symptoms begin, when interventions may be most effective.

The team analyzed hundreds of brain scans from people in various stages of Alzheimer's and found that the entorhinal cortex and amygdala began to shrink before the hippocampus, the main region of the brain responsible for memory, where doctors typically look for evidence of Alzheimer's.

"We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms," said biomedical engineer and senior author Michael Miller.

"It's at least a five- to 10-year play where your brain is changing. Imagine if we could start to treat the neurodegenerative changes at the two-, three- or four-year point rather than after 15 years when the changes are manifesting in memory symptoms. That's the great promise here for your loved ones who are at risk."

The work, published in NeuroImage: Reports, was presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.

Tracing the earliest brain changes

Alzheimer's disease is the leading cause of dementia worldwide. Researchers know that the disease begins to build in the brain decades before symptoms of memory loss appear, and they suspect that treatments would be most effective during those early years. So, developing reliable biomarkers for the earliest stages of the disease is critical.

"Our goal is to be able to treat individuals before the symptoms of Alzheimer's disease develop so that they may be delayed or even stopped," said Marilyn Albert, co-author and director of the Johns Hopkins Alzheimer's Disease Research Center.

The team analyzed hundreds of magnetic resonance imaging (MRI) and positron emission tomography (PET) scans from two independent cohorts, the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. The scans were taken over time from Alzheimer's patients who were symptom-free, who suffered cognitive impairment and who died from the disease.

Across patients from both studies, two brain regions near the hippocampus, the entorhinal cortex and the amygdala, showed greater atrophy and volume loss relative to the hippocampus during the early phase of the disease, the team found.

The entorhinal cortex is responsible for retrieving old memories. The amygdala is linked to emotional memory.

The team also demonstrated that gray matter atrophy was spatially localized with changes in tau protein as measured by PET imaging and digital pathology. Tau pathology is a known hallmark of Alzheimer's.

Toward earlier risk assessment

The team believes measuring atrophy in these two regions together could be a better early predictor of Alzheimer's disease and a promising new biomarker, especially as brain scanning technology becomes more available and affordable.

For people with a family history of Alzheimer's or other concerns, doctors might start scanning those new brain regions when patients are in their 30s and 40s.

"As biomarkers and treatments become increasingly available, knowing who is going to have cognitive decline is going to be really important," said co-author Meaghan Morris, a neuropathologist who studies Alzheimer's and other dementias. "This could really play into better risk stratification for identifying who is going to have cognitive decline in the near future—and treating people earlier and earlier to hopefully slow the course of the disease."

Molecular clues remain to be mapped

More work is needed before the findings can be used to help diagnose Alzheimer's.

The team hopes to zoom in on these key brain areas to learn more about what's happening at the molecular level as the disease begins to progress.

"Our future work is to better show the molecular neighborhoods associated with these tau protein changes as localized by these clinical biomarkers of atrophy," Miller said. "Once we know more about the molecular neighborhoods, we can develop therapies."

More information

Michael I. Miller et al., Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum, NeuroImage: Reports (2026). DOI: 10.1016/j.ynirp.2026.100392

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Brain scans reveal two regions that shrink before the hippocampus in Alzheimer's (2026, November 16) retrieved 16 November 2026 from https://medicalxpress.com/news/2026-11-brain-scans-reveal-regions-hippocampus.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com